Market Access

Value-based price for access (VBPA) may increase access of specialty drugs for patients.

Using data visualizations to improve access to payers.

New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.

Reversing non-formulary status will usually require new data.

Kalidas spoke with Pharm Exec about her efforts to bring equity to underserved patients and their communities through Bayer’s Oncology Sustainability Initiative.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.

This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.

Tackling the subjective limits of value proposition.

Assessing the road ahead for Chinese biotech.

Payers not looking to favor one product.

Forging effective partnerships with local companies is particularly important when entering Brazil’s pharma market. Sameer Kolhe reports.

New technology forces industry to increase urgency.

Potential for quality equivalent to economies of scale.

Emerging limits of one-year payer time frames.

Scientific advances are benefiting cancer patients, but it will take a pandemic-like response to ensure patients everywhere have access.

Faster launch planning leads to greater access.

The top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.

Examining why the cost and administration of these treatments are well suited to managed entry agreements—and which approach to MEA may prove to be the most commercially viable for manufacturers.

The BCG Market Access Roundtable presents an updated view of its access competencies framework first published five years ago.

A look at how VBC agreements between drug manufacturers and payers—which reimburse for pre-specified treatment outcomes—have measured up so far in reducing healthcare costs, and the opportunities still untapped to drive true value for both sides and the patients they serve.

Chance Scott shares insights on the benefits of evolving the role and integration of your reimbursement policy team to serve as market access partners and propellants, as well as the best practices for how to do so.

A focus on medical affairs and medical science liaisons.

Pandemic-reinforced principles of successful drug launch.

In today’s fragmented commercial environment, navigating a more complex set of challenges while adapting new approaches to product launch is critical for biopharma brand teams.